BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? [Yahoo! Finance]
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Yahoo! Finance
The cancer diagnostics industry is evolving rapidly as advances in biotechnology, data analytics and precision medicine continue to reshape how diseases are detected and managed. Within this landscape, bioAffinity Technologies, Inc. BIAF and Guardant Health, Inc. GH represent two distinct approaches to cancer diagnostics and molecular testing. While both companies operate in the broader oncology diagnostics space, their strategies differ in technological focus, product scope and market positioning. bioAffinity is primarily focused on developing non-invasive diagnostic tests aimed at the early detection of lung cancer and other lung diseases. The company's platform combines flow cytometry with automated data analysis supported by machine learning to identify cell populations associated with disease. Its lead product, CyPath Lung, analyzes sputum samples to detect cellular characteristics that may indicate the presence of lung cancer, offering physicians an additional diagnostic tool
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma PatientsBusiness Wire
- bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer TestBusiness Wire
- New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung CancerBusiness Wire
- Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case StudyBusiness Wire
- bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory BoardBusiness Wire
BIAF
Sec Filings
- 3/5/26 - Form PRE
- 3/3/26 - Form 8-K
- 2/25/26 - Form 8-K
- BIAF's page on the SEC website